Insulin glargine-aldy official document review · version 1
This page preserves this version's findings, scope and source pins. Open the current profile →
Inside the official reviews
Reviewed 2026-09-19 · Preserved version 1
The approval is tied to an exact biosimilar identity
FDA’s April 2026 letter licenses Langlara, insulin glargine-aldy, under BLA 761412. The reference product is US-Lantus; this should not be confused with other insulin-glargine suffixes or applications. FDA PDF pp. 1 ↗
More findings, study links and document coverage
Biosimilarity and interchangeability are product-specific findings
The letter addresses the specified Langlara presentation as biosimilar to and interchangeable with the specified US-Lantus presentation. It is not a ranking of all insulin products or permission to treat their presentations as identical. FDA PDF pp. 1 ↗
The letter and clinical-trial evidence serve different purposes
This approval letter records a licensing decision and the glycemic-control indication. It does not supply a trial-level comparative efficacy analysis; the separate label account explains which insulin-glargine studies its label summarizes. FDA PDF pp. 1 ↗
Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.
Document coverage
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Langlara: FDA approval letter ↗
Selected sections reviewed · fda-langlara-approval-2026 · Document/feed date: 2026-04-29
Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.
Verified: Langlara · BLA 761412 · Document dated 2026-04-29. Identity checked on PDF pp. 1, 6.
Approval-letter identity, licensing language and signature date only. This is not a clinical-review or trial-level appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 6 of 6. SHA-256:
ef59f1e69d9b3f9045e067d76c1c602dac9f20ab90520c2e7535832db50ab5dc.
Remaining work
- Locate and read the product-specific biosimilarity and interchangeability review behind BLA 761412.
- Reconcile current branded and unbranded labeling without assigning evidence from a different insulin-glargine suffix.